Septerna (NASDAQ:SEPN) Coverage Initiated by Analysts at Cantor Fitzgerald

Research analysts at Cantor Fitzgerald initiated coverage on shares of Septerna (NASDAQ:SEPN) in a research note issued to investors on Tuesday, MarketBeat reports. The firm set an “overweight” rating and a $50.00 price target on the stock. Cantor Fitzgerald’s price target points to a potential upside of 122.22% from the stock’s previous close.

Separately, TD Cowen initiated coverage on shares of Septerna in a report on Tuesday. They set a “buy” rating on the stock.

Septerna Stock Down 7.0 %

Shares of Septerna stock opened at $22.50 on Tuesday. Septerna has a one year low of $18.62 and a one year high of $26.34.

Insider Activity

In related news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the company’s stock in a transaction on Monday, October 28th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the completion of the transaction, the insider now directly owns 6,215,591 shares in the company, valued at approximately $111,880,638. The trade was a 6.34 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.